Hims & Hers continues to sell compounded semaglutide, the active ingredient in Novo’s Wegovy and Ozempic drugs, and these ...

Hims & Hers Health (NYSE:HIMS) said it is holding discussions with Novo Nordisk (NYSE:NVO) to make the Danish drugmaker's ...

Hims and Hers Health beat Wall Street estimates for third-quarter revenue on Monday, as the telehealth company added ...

Hims & Hers Health has appointed Deb Autor as its first chief policy officer to lead public policy and government functions, ...

Discover why Hims & Hers Health (HIMS) remains a strong long-term buy after robust Q3 growth, new offerings, and expansion ...

Less than six months after ending a short-lived partnership, US telehealth firm Hims & Hers (Nasdaq: HIMS) and Danish ...

Now, it’s worth noting Stock Advisor’s total average return is 1,036% — a market-crushing outperformance compared to 191 % ...

Market observers now await further developments regarding the potential Novo Nordisk partnership. Should Hims & Hers successfully secure the Wegovy distribution agreement, the company could maintain ...

Novo Nordisk cuts obesity drug prices to compete with Eli Lilly, offering new patient deals and nationwide access.

Hims & Hers Health, Inc. (NYSE:HIMS) saw its shares edge 1.5% higher on Monday after unveiling a fresh $250 million stock ...

Hims & Hers Health delivered a mixed earnings report and announced a potential Wegovy partnership with Novo Nordisk; the ...

After a tumultuous year, a popular virtual care platform is trying its hand in a competitive blood testing market.